Industry allows accessibility to treatment with Cannabidiol produced 100% nationally. Photo: Prati-Donaduzzi Press.
The new presentations of Cannabidiol developed by Prati-Donaduzzi pharmaceutical industry are now available in pharmacies. The first one to market the 20 mg/mL and 50 mg/mL products is São João Pharmacy chain. The most affordable treatment with the first and only Cannabidiol produced 100% nationally is already a reality throughout Brazil.
The new concentrations reach the market at lower prices, fulfilling the pharmaceutical company´s commitment to the health of Brazilians, by making treatment more accessible to the population and expanding prescription alternatives for health care professionals, enabling treatments with lower concentrations for different pathologies.
“Nowadays, Cannabidiol Prati-Donaduzzi at 200 mg/mL concentration contains 6,000 mg of Cannabidiol per 30 mL bottle. The new presentations offer a solution for those seeking treatment in lower concentrations for different pathologies and cheaper options”, says Prati-Donaduzzi CEO, Eder Fernando Maffissoni.
The new products will be available in oral solution, in the presentation of 30 mL, which means that in the concentration of 50 mg/mL there will be 1,500 mg of Cannabidiol per bottle and the 20 mg will contain 600 mg.
Last month, on February 22, Prati-Donaduzzi pharmaceutical industry received authorization from the National Health Regulatory Agency (Anvisa) to market two new concentrations of its product Cannabidiol, 20 mg/mL and 50 mg/mL. Since last year, the company has counted on the innovative product, at a concentration of 200 mg/mL.
All concentrations of Cannabidiol Prati-Donaduzzi are versions of the drug that is in the final stage of a phase III clinical study, through a public-private partnership between Prati-Donaduzzi and the Ribeirão Preto School of Medicine (FMRP) of the University of São Paulo.
In order to provide health and well-being to millions of Brazilians, Prati-Donaduzzi plans to increase the possibilities of treatment, especially for diseases that affect the Central Nervous System (CNS).
Currently, the industry has more than 400 presentations available to the population. By the end of this year, an expansion of the portfolio is planned with new launches indicated to treat diseases such as epilepsy, Parkinson's, Alzheimer's, anxiety, depression, neuropathic pain, schizophrenia, autism, bipolar and insomnia.